News

Five Things to Consider When Participating in a Clinical Trial

Five Things to Consider When Participating in a Clinical Trial

Facing a diagnosis can be a daunting journey, rife with uncertainty and difficult decisions. Among these decisions is the choice of whether to participate in a clinical trial. While the prospect may initially seem overwhelming, it’s essential to recognise the potential benefits and weigh them against the uncertainties.

In this guide, we’ll explore five critical factors to consider when contemplating clinical trial participation, empowering patients to navigate this complex terrain with confidence and clarity.

The unknowns of clinical trials

Clinical trials are ventures into uncharted territory, where new treatments are put to the test. Regardless of the trial’s phase, uncertainties abound.

From unknown side effects to the efficacy of the treatment in diverse patient populations, there’s much to ponder.

However, knowledge is power. Ensure you have read the consent form and engage with your clinician to unravel these uncertainties. Ask probing questions to obtain as much information as possible. Understanding the risks and potential benefits is key to making an informed decision.

Different healthcare teams

Entering a clinical trial may introduce you to a new ensemble of healthcare professionals or reframe your interactions with existing ones. From clinical trial nurses to coordinators and investigators, you’ll encounter a diverse array of experts dedicated to advancing cancer treatment. While the faces may change, the overarching goal remains constant: to find the best possible treatments for patients.

Embrace this collaborative effort, recognising that each member of the team plays a vital role in your journey. Getting to know your new team and respecting their efforts will put you at ease in this process.

Risks associated with clinical trials

Every clinical trial comes with its own set of risks, outlined meticulously in the Participant Information and Consent Form (PICF). Think of this document as your guidebook, offering insights into potential side effects and uncertain outcomes. Take the time to digest its contents thoroughly.

Adverse events, or unexpected side effects, play a pivotal role in the evaluation of medical interventions within clinical trials. During the clinical trial phase of drug development, fewer patients have been exposed to the drug so not all information about side effects is known. Pharmaceutical companies meticulously compile data on the effects of their drugs across various trials, documenting both anticipated and unforeseen reactions in an investigator brochure. This document must accompany a clinical trial and it is updated annually and distributed to all investigators working on the clinical trial.

In addition, all adverse events, regardless of severity or presumed cause, are diligently recorded during clinical trials. It is a collaborative effort between clinicians and pharmaceutical professionals to discern whether these events are directly linked to the drug being tested or are incidental occurrences.

A side effect that is believed to be related to the drug and not yet known will be rapidly reported and evaluated. Listings of these side effects are distributed to the clinical team on any clinical trial using the same drug, and are regularly reviewed to ensure that your trial is safe to continue. This process is conducted under stringent regulatory guidelines, ensuring appropriate safety oversight in the evaluation of new treatments. By meticulously documenting and analysing adverse events, researchers can enhance patient safety and refine our understanding of a drug’s potential benefits and risks.

Discuss any concerns with your healthcare team, leveraging their expertise to navigate the complexities of risk assessment. It is okay to seek information from another healthcare professional to gather additional information and insight. Ultimately, the decision to participate hinges on a careful balancing of risks and potential benefits.

Time and protocol

Participating in a clinical trial often entails adherence to a predefined protocol governing treatment procedures, appointments, and data collection processes. This protocol may necessitate adjustments to your daily routine or medication regimen. You may need to stop certain medication and be required to have study visits that are longer than normal visits. If required, this information will be in the consent form.
Before committing, take stock of these requirements. Consult with your healthcare and support team to assess the feasibility of accommodating these changes in your life. Open communication is key to ensuring that the trial aligns with your lifestyle and health goals.

Acceptance of uncertainty 

Signing the consent form marks the beginning of your journey into the clinical trial realm. However, it’s crucial to acknowledge the possibility of non-selection. Initial screening tests may reveal that the trial is not a suitable fit for you, primarily due to safety considerations. While this may be disheartening, rest assured that your clinician will continue to provide you with the best possible care, prioritising your well-being above all else. Lean on your support system during this time, drawing strength from their unwavering encouragement and understanding.

Participating in a clinical trial is a deeply personal decision, shaped by a myriad of factors. By carefully considering the unknowns, embracing collaboration with healthcare teams, understanding risks, evaluating time commitments, and accepting uncertainties, you can approach this decision-making process with clarity and confidence. Ultimately, the choice to participate in a clinical trial is a testament to your resilience and commitment to advancing medical science for the betterment of all.

Where do I find clinical trials?

If you are interested in participating in clinical trials there are various resources to find trials that align with your medical condition and treatment preferences. The Australian Clinical Trials has the most comprehensive databases for finding clinical trials.

Additionally, TOGA supports clinical trials for non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), mesothelioma, other thymic malignancies, supportive & palliative care, and translational research.

Share this

Facebook
Twitter
LinkedIn
Everything you need to know about the Australia-wide trial using liquid biopsy to guide treatment after targeted therapy progression in advanced lung cancer
The DEFIANT trial will evaluate datopotamab deruxtecan (Dato-DXd) in EGFR exon 20 insertion NSCLC after targeted therapy and chemotherapy.
Discover the major advances from TOGA ASM 2026, including lung cancer screening, precision medicine, immunotherapy, survivorship and multidisciplinary care shaping the future of thoracic oncology.
Professor Robert Stirling OAM devoted his career to improving the lives of people with lung cancer through clinical excellence, research, education and compassionate leadership.
Their work is often invisible, but its impact isn't. Specialist Lung Cancer Nurses are quietly becoming the backbone of modern lung cancer care.
Teletrials, also known as digi trials, are when a clinician at a primary site uses telehealth (videoconference or telephone calls) to enrol, consent, treat and/or
A simple guide to what happens after a lung CT scan in the Australian National Lung Cancer Screening Program
Updates from our Inspirational Research Grant 2025 recipients on pioneering lung microbiome research and its impact on immunotherapy efficacy.
Clinicians, nurses, consumers and health service leaders came together at TOGA’s Lung Cancer Optimal Care Pathway workshop to examine why Australia continues to struggle to
Understanding the language helps patients, families and clinicians stay informed, confident and part of the conversation.
TOGA is pleased to announce the latest appoints for our Scientific Committee.
Discover how a vibrant Lunar New Year Banquet, organised by Dr. Angeline Low and Ms. Maria Chan, raised over $50,000 for vital lung cancer research.
The MRFF is holding $1B+ in unspent funds. Learn why TOGA is calling for the release of this research funding to accelerate lung cancer breakthroughs
Discover TOGA’s FY25 highlights, including the new Strategic Plan, clinical trial milestones and record membership growth across Australia and New Zealand.
The Preventative and Quality Care Working Group represents TOGA’s commitment to improving the outcomes of thoracic cancers.
TOGA’s Working Groups are evolving to better reflect where thoracic cancer research is heading: From prevention and early detection through to advanced disease and living
Learn how to turn your endorsed research concept into a clinical trial; from sponsor selection to budgeting, data, safety and protocol design.
Learn how to design an investigator-initiated clinical trial, from refining your research idea to securing TOGA endorsement and funding.
Learn why EGFR-positive lung cancer disproportionately affects Asian populations and non-smokers. Discover modern targeted therapies and symptoms to watch for.
Discover how 2025 transformed lung cancer care in Australia. Explore the impact of national screening, modern diagnostics, and new PBS treatment approvals.
Let's take a moment to celebrate the incredible guests, ground breaking discussions, and dedicated listeners that made 2025 our most successful year yet.
If you are interested in joining TOGA on a Committee, please submit your nominations by 30 January 2026
The final Scientific Meeting of 2025 was held in November. Five concepts were presented, spanning both Recurrent and Metastatic NSCLC populations and four Mesothelioma concepts.
Bispecific antibodies target two pathways at once, reshaping lung cancer treatment through dual checkpoint blockade and targeted precision.
Research advances only improve outcomes when they are accessible to patients. TOGA drives change in lung cancer care by advocating through stakeholder submissions, including PBS.......
We are excited about awarding new grants but first, we check in on progress made by our 2024 recipients....
Learn how TOGA’s ASPiRATION study led to Medicare-funded genomic testing for lung cancer and national best practice guidelines in Australia.
Optimise cancer care for older Adults with practical tips and tools to implement person-centred geriatric oncology.
DYNAMALK is a significant clinical trial investigating the potential of comprehensive genomic profiling to revolutionise the treatment of ALK+ Non-Small Cell Lung Cancer (NSCLC)
Liquid biopsy is revolutionising lung cancer care by using a blood test to examine the tumour without the need for a lung biopsy.
OCEANiC will determine if patients with resected stage II to IIIA EGFR mutant NSCLC require intensification of osimertinib monotherapy with chemotherapy.
Latest results from the SHERLOCK clinical trial show promising first-line outcomes for patients with KRAS G12C-mutated lung cancer, combining sotorasib with chemotherapy and bevacizumab.
A re-cap of the Scientific Committee meeting in August 2025 and the year to date.
Celebrating TOGA's leadership transition: We honour the service of our past Board members and welcome the new Chair and Directors who will chart TOGA’s future.
Why doesn’t immunotherapy work for all lung cancer patients? This article breaks down T-cell resistance mechanisms and what clinical trials are doing to overcome them.
Precision medicine has revolutionised lung cancer treatment by matching therapies to a patient’s genetic profile. Learn more.....